Oncodesign Precision Medicine Société anonyme (ALOPM.PA)
Paris · EUR · Healthcare · Biotechnology
€0.257 (+0.39%) as of
Key statistics
- Market cap
- 4.90M
- P/E (TTM)
- 0.86
- Forward P/E
- 0.48
- EPS (TTM)
- 0.3000
- Dividend yield
- 0.00%
- 52-week range
- 0.2000 – 0.9200
- Beta
- -0.65
- Revenue (TTM)
- 1.82M
- Profit margin
- 0.00%
- Volume
- 47.24k
About Oncodesign Precision Medicine Société anonyme
Oncodesign Precision Medicine Société anonyme, a biopharmaceutical company, engages in the precision medicine business. The company's product pipeline consist of OPM-101, a RIPK2 inhibitor for the treatment of inflammatory bowel disease and immuno-oncology; OPM-102 to treat cancer; and OPM-201, a LRRK2 inhibitor for the treatment of Parkinson's disease. It also focuses on the development of a radiotheranostic molecule portfolio for the diagnosis and the treatment of advanced digestive cancers under PROMETHE brand; Nanocyclix, a kinase inhibitors, as well as on developing treatment for pancreatic and other cancers. Oncodesign Precision Medicine Société anonyme was founded in 1995 and is based in Dijon, France.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Dijon, France
- Employees
- 14
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.